News items related to:
-
Lenacapavir Patent Faces Opposition at the Eurasian Patent Office
“If Gilead Science’s patent application regarding Lenacapavir is granted, the patent will represent another significant barrier to the affordable access...
-
Major Win: First Batch of Dolutegravir Arrives in Colombia Under a Compulsory License
The World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all population groups. In Colombia, access...
-
Empowering Africa’s Pharmaceutical Future: Local Manufacturing and IP Reform as Game-Changers
The African pharmaceutical market is on the rise, with its value soaring to $25 billion in 2022 and projected to...
-
ITPC-EECA Challenges Patents on core DR-TB Drug Pretomanid, Urging Eurasian Patent Office to Protect Access
According to WHO, 400,000 people developed DR-TB in 2023, yet only 44% (175, 923) of them were treated for it....
-
Ukrainian Patient Rights Group Opposes a Patent Applications on a Life-Saving HIV Drug
Rilpivirine, commonly known as RPV, is available in multiple formulations, including a daily oral medication, and in fixed-dose combination tablets,...
-
10th December Human Rights Day 2024: Achieving Equity in HIV Treatment and Prevention
On this Human Rights Day, the Global Network of People Living with HIV (GNP+) and the International Treatment Preparedness Coalition...
-
‘HIV Transmission Can be Stopped’: Leading HIV Researchers Make the Case for Compulsory Licensing of Lenacapavir
Lenacapavir (LEN), a groundbreaking, long-acting antiretroviral, has prevented nearly all HIV infections in clinical trials. LEN could be the answer...